BMJ Best Practice

参考文献

关键文献

Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol. 2013;9:544-556.

Fox RI. Sjogren's syndrome. Lancet. 2005;366:321-331.

Haugen AJ, Peen E, Hulten B, et al. Estimation of the prevalence of primary Sjogren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordland Health Study. Scand J Rheumatol. 2008;37:30-34.

Harris VM, Sharma R, Cavett J, et al. Klinefelter's syndrome (47,XXY) is in excess among men with Sjogren's syndrome. Clin Immunol. 2016;168:25-29.

Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol. 2006;2:252-261.

Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2004;18:313-329.

Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.

Whitcher JP, Shiboski CH, Shiboski SC, et al; Sjogren's International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol. 2010;149:405-415.

Hernández-Molina G, Avila-Casado C, Nuñez-Alvarez C, et al. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjogren's syndrome in patients with systemic autoimmune diseases in the clinical setting. Rheumatology (Oxford). 2015;54:441-448.

Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233-242.

参考文章

1.  Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol. 2013;9:544-556.

2.  Fox PC. Autoimmune diseases and Sjogren's syndrome, an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007;1098:15-21.

3.  Anaya JM, Tobon GJ, Vega P, et al. Autoimmune disease aggregation in families with primary Sjogren's syndrome. J Rheumatol. 2006;33:2227-2234.

4.  Steinberg AD, Talal N. The coexistence of Sjogren's syndrome and systemic lupus erythematosus. Ann Intern Med. 1971;74:55-61.

5.  Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med. 1979;66:733-736.

6.  Foster H, Fay A, Kelly C, et al. Thyroid disease and other autoimmune phenomena in a family study of primary Sjogren's syndrome. Br J Rheumatol. 1993;32:36-40.

7.  Alarcon-Segovia D, Ibanez G, Hernandez-Ortiz J, et al. Sjogren's syndrome in progressive systemic sclerosis (scleroderma). Am J Med. 1974;57:78-85.

8.  Manthorpe R, Manthorpe T. Primary Sjogren's syndrome - epidemiology and prognosis. Akt Rheumatol. 2005;30:27-31.

9.  Fox RI. Sjogren's syndrome. Lancet. 2005;366:321-331.

10.  Kabasakal Y, Kitapciglu G, Turk T, et al. The prevalence of Sjogren's syndrome in adult women. Scand J Rheumatol. 2006;35:379-383.

11.  Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164:1275-1284.

12.  Haugen AJ, Peen E, Hulten B, et al. Estimation of the prevalence of primary Sjogren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordland Health Study. Scand J Rheumatol. 2008;37:30-34.

13.  Schein OD, Hochberg MC, Muñoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159:1359-1363.

14.  Scofield RH, Kurien BT, Reichlin M. Immunologically restricted and inhibitory anti-Ro in monozygotic twins. Lupus. 1997;6:395-398.

15.  Bolstad AI, Haga HJ, Wassmuth R, et al. Monozygotic twins with primary Sjogren's syndrome. J Rheumatol. 2000;27:2264-2266.

16.  Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol. 2006;2:262-269.

17.  Gottenberg JE, Busson M, Loiseau P, et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003;48:2240-2245.

18.  Scofield RH. Genetics of systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol. 2009;21:448-453.

19.  Nagata Y, Inoue H, Yamada K, et al. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology. 2004;111:223-229.

20.  Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren's syndrome. Transl Res. 2006;148:281-288.

21.  Scheinfeld N. Sjogren syndrome and systemic lupus erythematosus are distinct conditions. Dermatol Online J. 2006;12:4.

22.  Hammi AR, Al-Hashimi IH, Nunn ME, et al. Assessment of SS-A and SS-B in parotid saliva of patients with Sjogren's syndrome. J Oral Pathol Med. 2005;34:198-203.

23.  Miller AV, Ranatunga SK, Francis ML, et al. Sjogren syndrome. August 2016. http://emedicine.medscape.com/ (last accessed 28 September 2017).

24.  Lemp MA. Dry eye (keratoconjunctivitis sicca), rheumatoid arthritis, and Sjogren's syndrome. Am J Ophthalmol. 2005;140:898-899.

25.  Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2:777-780.

26.  Ackerman LS. Sex hormones and the genesis of autoimmunity. Arch Dermatol. 2006;142:371-376.

27.  Sullivan DA, Belanger A, Cermak JM, et al. Are women with Sjogren's syndrome androgen-deficient? J Rheumatol. 2003;30:2413-2419.

28.  Delaleu N, Jonsson R, Koller MM. Sjogren's syndrome. Eur J Oral Sci. 2005;113:101-113.

29.  Liu K, Kurien BT, Zimmerman SL, et al. X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,XXX in systemic lupus erythematosus and Sjogren's syndrome. Arthritis Rheumatol. 2016;68:1290-1300.

30.  Harris VM, Sharma R, Cavett J, et al. Klinefelter's syndrome (47,XXY) is in excess among men with Sjogren's syndrome. Clin Immunol. 2016;168:25-29.

31.  Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol. 2006;2:252-261.

32.  Cimaz R, Casadei A, Rose C, et al. Primary Sjogren’s syndrome paediatric age: a multicentre survey. Eur J Pediatr. 2003;162:661-665.

33.  Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2004;18:313-329.

34.  Fox PC, Brennan M, Pillemer S, et al. Sjogren's syndrome: a model for dental care in the 21st century. J Am Dent Assoc. 1998;129:719-728.

35.  Shiboski SC, Shiboski CH, Criswell L, et al; Sjogren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64:475-487.

36.  Scofield AK, Radfar L, Ice JA, et al. Relation of sensory peripheral neuropathy in Sjogren syndrome to anti-Ro/SSA. J Clin Rheumatol. 2012;18:290-293.

37.  Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82:798-802.

38.  Agmon-Levin N, Kivity S, Tzioufas AG, et al. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. J Autoimmun. 2012;39:234-239.

39.  Napeñas JJ, Rouleau TS. Oral complications of Sjogren's syndrome. Oral Maxillofac Surg Clin North Am. 2014;26:55-62.

40.  Al-Hashimi I, Khuder S, Haghighat N, et al. Frequency and predictive value of the clinical manifestations in Sjogren's syndrome. J Oral Pathol Med. 2001;30:1-6.

41.  Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33:95-106.

42.  Klasser GD, Balasubramaniam R, Epstein J. Topical review-connective tissue diseases: orofacial manifestations including pain. J Orofac Pain. 2007;21:171-184.

43.  Chung WS, Lin CL, Sung FC, et al. Increased risks of deep vein thrombosis and pulmonary embolism in Sjogren syndrome: a nationwide cohort study. J Rheumatol. 2014;41:909-915.

44.  Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.

45.  Colella G, Cannavale R, Vicidomini A, et al. Salivary gland biopsy: a comprehensive review of techniques and related complications. Rheumatology (Oxford). 2010;49:2117-2121.

46.  Jonsson MV, Baldini C. Major salivary gland ultrasonography in the diagnosis of Sjogren’s syndrome - a place in the diagnostic criteria? Rheum Dis Clin North Am. 2016;42:501-517.

47.  Zhang X, Zhang S, He J, et al. Ultrasonographic evaluation of major salivary glands in primary Sjogren's syndrome: comparison of two scoring systems. Rheumatology (Oxford). 2015;54:1680-1687.

48.  Luciano N, Baldini C, Tarantini G, et al. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjogren's syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015;54:2198-2204.

49.  Takagi Y, Sumi M, Nakamura H, et al. Ultrasonography as an additional item in the American College of Rheumatology classification of Sjogren's syndrome. Rheumatology (Oxford). 2014;53:1977-1983.

50.  Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sjogren's syndrome. Ann Rheum Dis. 1998;57:291-295.

51.  Gudbjornsson B, Broman JE, Hetta J, et al. Sleep disturbances in patients with primary Sjogren's syndrome. Br J Rheumatol. 1993;32:1072-1076.

52.  Strombeck B, Ekdahl C, Manthorpe R, et al. Physical capacity in women with primary Sjogren's syndrome: a controlled study. Arthritis Rheum. 2003;49:681-688.

53.  Newbrun E. Current treatment modalities of oral problems of patients with Sjogren's syndrome: caries prevention. Adv Dent Res. 1996;10:29-34.

54.  Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol. 2005;5:4.

55.  Tucci M, Quatraro C, Silvestris F. Sjogren's syndrome: an autoimmune disorder with otolaryngological involvement. Acta Otorhinolaryngol Ital. 2005;25:139-144.

56.  Segerberg-Konttinen M, Konttinen YT, Bergroth V. Focus score in the diagnosis of Sjogren's syndrome. Scand J Rheumatol Suppl. 1986;61:47-51.

57.  Whitcher JP, Shiboski CH, Shiboski SC, et al; Sjogren's International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol. 2010;149:405-415.

58.  Daniels TE, Benn DK. Is sialography effective in diagnosing the salivary component of Sjogren's syndrome? Adv Dent Res. 1996;10:25-28.

59.  Nicholson DA. Contrast media in sialography: a comparison of Lipiodol Ultra Fluid and Urografin 290. Clin Radiol 1990;42:423-426.

60.  Hernández-Molina G, Avila-Casado C, Nuñez-Alvarez C, et al. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjogren's syndrome in patients with systemic autoimmune diseases in the clinical setting. Rheumatology (Oxford). 2015;54:441-448.

61.  Shiboski S, Shiboski C; EULAR Sjogren’s Syndrome Classification Criteria Working Group. Proposed ACR-EULAR classification criteria for Sjogren’s syndrome: development and validation. Abstract S1.1. 13th International Symposium on Sjogren’s Syndrome, May 2015; Bergen, Norway. http://www.sicca.org/ (last accessed 28 September 2017).

62.  Shiboski CH. New ACR-EULAR Sjogren’s syndrome classification criteria and updates. Abstract. American College of Rheumatology National Meeting, September 2015; San Francisco, CA.

63.  Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA. 2010;304:452-460.

64.  Kalk WW, Mansour K, Vissink A, et al. Oral and ocular manifestations in Sjogren's syndrome. J Rheumatol. 2002;29:924-930.

65.  Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allergy Asthma Rep. 2005;5:327-332.

66.  Jacobi C, Cursiefen C. Ophthalmological complications in Sjogren's syndrome [in German]. Z Rheumatol. 2010;69:32-40.

67.  Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Punctal occlusion in Sjogren's syndrome needs clarification. Nat Rev Rheumatol. 2012;8:752.

68.  Zandbelt MM, van den Hoogen FH, de Wilde PC, et al. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren's syndrome. Ann Rheum Dis. 2001;60:511-513.

69.  Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren's syndrome. Clin Rev Allergy Immunol. 2007;32:284-291.

70.  Mavragani CP, Moutsopoulos HM. Immunosuppression and immunomodulation in Sjogren’s syndrome - what is the evidence? Does it relieve the sicca symptoms? Aktuelle Rheumatologie. 2005;30:66-70.

71.  Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjogren’s syndrome. Clin Exp Rheumatol. 1993;11:149-156.

72.  Akpek EK, Lindsley KB, Adyanthaya RS, et al. Treatment of Sjogren's syndrome-associated dry eye: an evidence-based review. Ophthalmology. 2011;118:1242-1252.

73.  Gündüz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren’s syndrome. Acta Ophthalmol (Copenh). 1994;72:438-442.

74.  Fan WS, Hung HL, Liao HP, et al. Topical cyclosporine therapy for keratoconjunctivitis sicca in Sjogren’s syndrome. Tzu Chi Med J. 2003;15:85-89.

75.  Drosos AA, Skopouli FN, Galanopoulu VK, et al. Cyclosporin A therapy in patients with primary Sjogren's syndrome: results at one year. Scand J Rheumatol Suppl. 1986;61:246-249.

76.  Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sjogren’s syndrome: a double blind study. Ann Rheum Dis. 1986;45:732-735.

77.  Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol. 1996;14:555-558.

78.  Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol. 1995;34:326-333.

79.  Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008;37:273-292.

80.  Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol. 2006;35:323-325.

81.  Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233-242.

82.  Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312:249-258.

83.  Manoussakis MN, Moutsopoulos HM. Anti-malarials in Sjogren's syndrome - the Greek experience. Lupus. 1996;5(suppl 1):28S-30S.

84.  Scofield RH. Vasculitis in Sjogren's Syndrome. Curr Rheumatol Rep. 2011;13:482-488.

85.  Doyle MK. Vasculitis associated with connective tissue disorders. Curr Rheumatol Rep. 2006;8:312-316.

86.  Wakasugi D, Kato T, Gono T, et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome. Mod Rheumatol. 2009;19:437-440.

87.  Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011;63:1339-1344.

88.  Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren's syndrome. J Neurol Sci. 2009;279:57-61.

89.  Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:28-46.

90.  Prause JU, Frost-Larsen K, Hoj L, et al. Lacrimal and salivary secretion in Sjogren's syndrome: the effect of systemic treatment with bromhexine. Acta Ophthalmol (Copenh). 1984;62:489-497.

91.  O'Neill ID, Scully C. Biologics in oral medicine: Sjogren syndrome. Oral Dis. 2013;19:121-127.

92.  Izumi M, Eguchi K, Nakamura H, et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome. Ann Rheum Dis. 1998;57:464-469.

93.  Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjogren syndrome. Eur J Ophthalmol. 2013;23:368-376.

94.  Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;(2):CD009327.

95.  López-García JS, García-Lozano I, Rivas L, et al. Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study. Acta Ophthalmol. 2014;92:e22-e29.

96.  Ba J, Wu Y, Li Y, et al. Updated meta-analysis of acupuncture for treating dry eye. Med Acupuncture. 2013;25:317-327.

97.  Vivino FB, Al-Hashimi I, Khan Z, et al; P92-01 Study Group. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med. 1999;159:174-181.

98.  Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol. 2007;32:265-274.

99.  Fox RI. Sjogren's syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs. 2000;9:2007-2016.

100.  Mariette X. Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis. 2001;60:1007-1010.

101.  Lynch DA. Lung disease related to collagen vascular disease. J Thorac Imaging. 2009;24:299-309.

使用此内容应接受我们的免责声明。